文献速递肝病消化道肿瘤与早癌

丙型肝炎病毒感染合并晚期纤维化患者获得持续病毒学应答后肝癌监测的成本效益

Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-12-20

该研究用马尔可夫模型评估50岁晚期纤维化患者抗丙肝治疗获持续病毒学应答后,每半年或每年超声监测肝癌的成本效益。肝硬化患者每半年监测具有成本效益,而F3纤维化患者每半年监测的ICER为188157美元/QALY,不具有成本效益。

要点

  • 肝硬化患者治疗后每半年超声监测肝癌具有成本效益。
  • F3纤维化患者每半年监测的ICER为188157美元/QALY。
  • 肝癌年发生率和无监测下症状进展率影响成本效益。

核心结论

  • 马尔可夫模型显示,丙肝治疗获持续病毒学应答后,肝癌监测对肝硬化患者具有成本效益,但对F3纤维化患者不具有成本效益。

研究设计与样本

  • 马尔可夫模型评估50岁晚期纤维化患者抗丙肝治疗获持续病毒学应答后,每半年或每年超声监测肝癌与不监测的成本效益,参数来自文献和专家意见。

主要发现

  • 肝癌年发生率恒定0.5%时,每半年和每年监测的ICER分别为106792美元/QALY和72105美元/QALY,假阳性率高。
  • 监测限于肝硬化(不含F3纤维化)患者时,每半年监测可能具有成本效益,干扰素和直接抗病毒药物治疗后ICER分别为48729美元/QALY和43229美元/QALY。
  • F3纤维化患者肝癌年发生率为0.3%至0.4%,每半年监测的ICER为188157美元/QALY。
  • 若肝癌发生率随年龄增加,监测更具成本效益,但仅在肝硬化或治疗前APRI大于2.0或FIB-4大于3.25的患者中低于支付意愿阈值。
  • 敏感性分析确定肝癌发生率和无监测下向症状性疾病转变率是影响成本效益的因素。

关键数值与推荐

  • 肝硬化患者每半年监测ICER为48729美元/QALY(干扰素治疗后)和43229美元/QALY(直接抗病毒药物治疗后)。
  • F3纤维化患者每半年监测ICER为188157美元/QALY。
  • 肝癌年发生率恒定0.5%时,每半年监测ICER为106792美元/QALY,每年监测ICER为72105美元/QALY。

临床怎么用

  • 作者认为,丙肝治疗获持续病毒学应答后,肝癌监测对肝硬化患者具有成本效益,但对F3纤维化患者不具有成本效益。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hepatitis C virus (HCV)-related cirrhosis increases the risk for hepatocellular carcinoma (HCC). After a sustained virologic response (SVR) to anti-HCV therapy, the risk of HCC is reduced but not eliminated. Recent developments in antiviral therapy have increased rates of SVR markedly. Guidelines recommend indefinite biannual ultrasound surveillance after SVR for patients with advanced fibrosis before treatment. Surveillance for HCC is cost effective before anti-HCV treatment; we investigated whether it remains so after SVR. METHODS: We developed a Markov model to evaluate the cost effectiveness of biannual or annual HCC ultrasound surveillance vs no surveillance in 50-year-old patients with advanced fibrosis after an SVR to anti-HCV therapy. Parameter values were obtained from publications and expert opinions. Primary outcomes were quality-adjusted life-years (QALYs), costs, and the incremental cost-effectiveness ratios (ICERs). RESULTS: With a constant 0.5% annual incidence of HCC, biannual and annual surveillance resulted in ICERs of $106,792 and $72,105 per QALY, respectively, with high false-positive rates. When surveillance was limited to patients with cirrhosis, but not F3 fibrosis, biannual surveillance likely was cost effective, with ICERs of $48,729 and $43,229 per QALY after treatment with interferon and direct-acting antiviral agents, respectively. In patients with F3 fibrosis, the incidence of HCC was 0.3% to 0.4% per year, leading to an ICER of $188,157 per QALY for biannual surveillance. If HCC incidence increases with age, surveillance becomes more cost effective but remains below willingness-to-pay thresholds only for patients with cirrhosis or with pretreatment aspartate aminotransferase to platelet ratio index greater than 2.0 or FIB-4 measurements greater than 3.25. Sensitivity analyses identified HCC incidence and transition rate to symptomatic disease without surveillance as factors that affect cost effectiveness. CONCLUSIONS: In a Markov model, we found HCC surveillance after an SVR to HCV treatment to be cost effective for patients with cirrhosis, but not for patients with F3 fibrosis.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Farhang Zangneh H, Wong WWL, Sander B, et al. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. Clin Gastroenterol Hepatol. 2018. PMID: 30580095. doi:10.1016/j.cgh.2018.12.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。